Colony-stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), is a cell-surface receptor for its ligands, colony-stimulating factor 1 (CSF1) and IL-34.1,2 CSF1R plays an important role as regulator of the development, morphology, survival, and functions of tissue macrophages as well as tumor-associated macrophages (TAMs). CSF1 is involved in the recruitment and survival of macrophages in tumors. Increased CSF1 expression is implicated in tumor progression and metastasis, and is associated with poor prognosis in some cancers.3 Molecule
LY3022855 (IMC-CS4) is a human IgG1 monoclonal antibody designed to target the CSF1R, preventing ligands CSF1 and IL-342 from binding to the receptor and inhibiting TAMs from receiving CSF1 signals, decreasing their survival and relieving the effect of TAMs in the tumor.4 Clinical Development
LY3022855 (IMC-CS4) is being investigated in phase I clinical trials, including a collaboration clinical trial with another immuno-oncology agent.
Locations United States, California Cedars Sinai Medical Center Recruiting Los Angeles, California, United States, 90048 Contact 646-888-5440 Principal Investigator: Heather McArthur United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact 646-422-4632 Principal Investigator: Karen Autio Sponsors and Collaborators Eli Lilly and Company
"How many non disclosed collaborations, being revealed....would help prove Ronin hedge fund is here only in light of some BP trying to steal PS Targeting..... "
What are you writing??? The best way to avoid a control via Ronin is to make a deal! So, where is the exosome-partnership?? Bavi, Cotaria, Imaging-Deal?:-)
Market Data 
Markets 
AI
